ライブラリ登録: Guest
Begell Digital Portal Begellデジタルライブラリー 電子書籍 ジャーナル 参考文献と会報 リサーチ集
Critical Reviews™ in Therapeutic Drug Carrier Systems
インパクトファクター: 2.9 5年インパクトファクター: 3.72 SJR: 0.736 SNIP: 0.818 CiteScore™: 4.6

ISSN 印刷: 0743-4863
ISSN オンライン: 2162-660X

巻:
巻 37, 2020 巻 36, 2019 巻 35, 2018 巻 34, 2017 巻 33, 2016 巻 32, 2015 巻 31, 2014 巻 30, 2013 巻 29, 2012 巻 28, 2011 巻 27, 2010 巻 26, 2009 巻 25, 2008 巻 24, 2007 巻 23, 2006 巻 22, 2005 巻 21, 2004 巻 20, 2003 巻 19, 2002 巻 18, 2001 巻 17, 2000 巻 16, 1999 巻 15, 1998 巻 14, 1997 巻 13, 1996 巻 12, 1995

Critical Reviews™ in Therapeutic Drug Carrier Systems

DOI: 10.1615/CritRevTherDrugCarrierSyst.2017020231
pages 65-97

Peroxisome Proliferated Activated Receptors (PPARs): Opportunities and Challenges for Ocular Therapy

Prachi Khatol
Pharmaceutics Research Projects Laboratory, Department of Pharmaceutical Sciences, Dr. Hari Singh Gour Central University, University Road, Sagar, Madhya Pradesh 470003, India
Shivani Saraf
Pharmaceutics Research Projects Laboratory, Department of Pharmaceutical Sciences, Dr. Hari Singh Gour Central University, University Road, Sagar, Madhya Pradesh 470003, India
Ankit Jain
Institute of Pharmaceutical Research, GLA University, 17km Stone, NH-2, Mathura-Delhi Road P.O. Chaumuhan, Mathura, Uttar Pradesh 281406, India

要約

Peroxisome proliferator-activated receptors (PPARs) are nuclear transcription factors. They exist in three isoforms (PPAR-α, PPAR-β/δ, and PPAR-Υ) in humans, but mainly PPAR-Υ, and they are expressed in retinal epithelial pigment. PPARs are involved in mediating numerous pathological implications in eye such as diabetic retinopathy (DR), choroidal neovascularization (CNV), glaucoma, diabetic macular edema, and other retinal diseases. Peroxisome proliferator-activated receptors are key players in various biological pathways like lipid degeneration, immune regulation, and reactive oxygen species regulation, regulation of vascular endothelial growth factor, matrixmetalloproteinase-9, and docosahexaenoic acid pathway. Based on evidence from clinical investigations, the drugs meant for PPARs could be promising candidates for intraocular therapy. Anti-VEGF therapy, including bevacizumab, ranibizumab, and aptamers (pegaptanib), has been approved for wet age-related macular degeneration (ARMD). Recently, researchers have explored the role of PPAR-γ in ocular pathophysiological processes and PPAR-γ agonists as novel adjuvants in the treatment of eye diseases. PPAR-γ exhibits potential benefits to improve or prevent various vision-threatening eye diseases such as age-related macular degeneration (ARMD), diabetic retinopathy (DR), keratitis, and optic neuropathy. However, PPAR-γ presents challenges and offers opportunities for ocular scientists to bring better outcomes.


Articles with similar content:

In Situ Gelling Polymers in Ocular Drug Delivery Systems: A Review
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.26, 2009, issue 1
Jasmine G. Avari, Atish S. Mundada
Applications and Risks of Nanomaterials Used in Regenerative Medicine, Delivery Systems, Theranostics, and Therapy
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.34, 2017, issue 1
Danae Garcia-Viacobo, Franklin A. Carrero- Martinez, Estefany I. Medina-Reyes, Yolanda Irasema Chirino
Retinal Pigment Epithelium Differentiation of Stem Cells: Current Status and Challenges
Critical Reviews™ in Biomedical Engineering, Vol.37, 2009, issue 4-5
Martin Yarmush, Basak E. Uygun, Nripen Sharma
Pharmacology of Endogenous Neuroactive Steroids
Critical Reviews™ in Neurobiology, Vol.15, 2003, issue 3&4
Doodipala Samba Reddy
A Review on Phosphorylcholine-Coated Stents
Journal of Long-Term Effects of Medical Implants, Vol.27, 2017, issue 2-4
Andrew L. Lewis, Peter W. Stratford